Business
BioLife Solutions Reports First Quarter 2026 Financial Results
BioLife Solutions, Inc. (Nasdaq: BLFS) ("BioLife" or the "Company"), a leading developer and supplier of cell processing tools and services for the cell and gene therapy ("CGT") market, announces financial results for the three months ended March 31, 2026.
About this update from Biolife Solutions, Inc.
[{"type":"text","content":"Total revenue of $27.5 million, up 25% over Q1 2025","length":51,"tagName":"p","attribs":{}},{"type":"text","content":"GAAP gross margin and non-GAAP adjusted gross margin of 64%","length":59,"tagName":"p","attribs":{}},{"type":"text","content":"GAAP net income of $1.2 million and non-GAAP adjusted EBITDA of $6.2 million or 22% of revenue","length":94,"tagName":"p","attribs":{}},{"type":"text","content":"Conference call begins at 4:30 p.m. Eastern time today","length":54,"tagName":"p","attribs":{}},{"type":"text","content":"BOTHELL, Wash., May 7, 2026 /PRNewswire/ -- BioLife Solutions, Inc. (Nasdaq: BLFS) ("BioLife" or the "Company"), a leading developer and supplier of cell processing tools and services for the cell and gene therapy ("CGT") market, announces financial results for the three months ended March 31, 2026.","length":345,"tagName":"p"},{"type":"image","alt":"BioLife Solutions Logo (PRNewsfoto/BioLife Solutions, Inc.)","displaySize":"","headline":null,"caption":"BioLife Solutions Logo (PRNewsfoto/BioLife Solutions, Inc.)","className":"","disableSlideshowImg":false,"size":{"original":{"width":400,"height":111,"url":"https://media.zenfs.com/en/prnewswire.com/2c77b8327844a4e269c45c61c477e453"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/HG4a1WwVeOW9V.QIo3u2MQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTE5Ng--/https://media.zenfs.com/en/prnewswire.com/2c77b8327844a4e269c45c61c477e453","width":400,"height":111},"resize_sm":{"url":"https://s.yimg.com/ny/api/res/1.2/prrnxKaCxxMYgpBVCiXrJQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTY0MDtoPTE3OA--/https://media.zenfs.com/en/prnewswire.com/2c77b8327844a4e269c45c61c477e453","width":400,"height":111}},"href":"https://mma.prnewswire.com/media/2827727/BioLife_Solutions__Logo.html","hrefExternal":true,"rel":"nofollow"},{"type":"text","content":""We delivered a solid start to 2026, with first quarter revenue up 25% year-over-year and adjusted EBITDA of $6.2 million," said Roderick de Greef, Chairman and Chief Executive Officer of BioLife Solutions. "Healthy demand for our biopreservation media and growth across our broader product portfolio reinforces our market leading position, while high-margin, recurring revenue drives a strong financial profile. Our products are embedded across a significant portion of commercial therapies and clinica...